International Journal of

ADVANCED AND APPLIED SCIENCES

EISSN: 2313-3724, Print ISSN: 2313-626X

Frequency: 12
line decor
  
line decor

 Volume 7, Issue 9 (September 2020), Pages: 35-42

----------------------------------------------

 Original Research Paper

 Title: Clopidogrel efficacy with concomitant drug therapy in patients undergoing percutaneous coronary intervention

 Author(s): Alhanouf S. Alsalloum 1, *, Tahani H. Ibrahim 2

 Affiliation(s):

 1College of Pharmacy, Qassim University, Buraydah, Saudi Arabia
 2Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, Saudi Arabia

  Full Text - PDF          XML

 * Corresponding Author. 

  Corresponding author's ORCID profile: https://orcid.org/0000-0002-1556-5755

 Digital Object Identifier: 

 https://doi.org/10.21833/ijaas.2020.09.006

 Abstract:

Clopidogrel, as an adjunct to aspirin, has been recommended for patients undergoing percutaneous coronary intervention (PCI) to reduce adverse cardiovascular events. Clopidogrel needs activation via the cytochromes P450 enzymes. Concomitant use of clopidogrel with drugs that utilize the same enzymatic pathway may interfere with its conversion to an active form. This study aims to assess the impact of concomitant drug therapy on clopidogrel efficacy in patients undergoing PCI and to identify the association between the use of those drugs and the risk of future adverse cardiac events. A total of 126 medical records for patients followed at King Fahad Specialist Hospital, and King Saud Hospital in Qassim, Saudi Arabia, were reviewed. Patients were divided into six groups: First group clopidogrel, second to fourth group clopidogrel plus proton pump inhibitors (PPIs)/calcium channel blockers (CCBs)/statins, fifth group clopidogrel with either PPIs, CCBs, statins, and sixth group clopidogrel plus PPIs, CCBs, and statins. Descriptive statistics were performed to detect the correlation between the concomitant drug used and MACEs. Out of the total number, 58 patients had MACEs. The correlation between MACEs and medications used in the groups of clopidogrel with PPIs, statins, or combinations of PPIs with CCBs and statins, or combination of two drugs had a MACEs rate of 12% (P= 0.027), 17.2% (P= 0.0041), 19% (P= 0.0021), 43.1% (P= 0.0001) respectively in comparison to 3.45% in the clopidogrel group. Therefore, concomitant use of clopidogrel with PPIs, statins, or combinations of PPIs with CCBs and statins, or a combination of two drugs is associated with a higher risk of MACEs. This suggests that these medications may attenuate the antiplatelet effect clopidogrel. Prospective randomized studies are needed to provide firm evidence for this interaction. 

 © 2020 The Authors. Published by IASE.

 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

 Keywords: Clopidogrel, Percutaneous coronary intervention, Proton pump inhibitors, Calcium-channel blockers, Statins

 Article History: Received 5 February 2020, Received in revised form 15 May 2020, Accepted 20 May 2020

 Acknowledgment:

No Acknowledgment.

 Compliance with ethical standards

 Conflict of interest: The authors declare that they have no conflict of interest.

 Citation:

 Alsalloum AS and Ibrahim TH (2020). Clopidogrel efficacy with concomitant drug therapy in patients undergoing percutaneous coronary intervention. International Journal of Advanced and Applied Sciences, 7(9): 35-42

 Permanent Link to this page

 Figures

 Fig. 1 Fig. 2

 Tables

 Table 1 Table 2 Table 3 Table 4

----------------------------------------------

 References (35)

  1. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, and Levine GN (2014). 2014 AHA/ACC guideline for the management of patients with non–st-elevation acute coronary syndromes: Executive summary: A report of the American college of cardiology/American heart association task force on practice guidelines. Circulation, 130(25): 2354-2394. https://doi.org/10.1161/CIR.0000000000000133   [Google Scholar] PMid:25249586
  2. Arbel Y, Birati EY, Finkelstein A, Halkin A, Kletzel H, Abramowitz Y, and Banai S (2013). Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: A prospective, randomized, crossover study. Clinical Cardiology, 36(6): 342-346. https://doi.org/10.1002/clc.22117   [Google Scholar] PMid:23630016 PMCid:PMC6649548
  3. Bates ER, Lau WC, and Angiolillo DJ (2011). Clopidogrel–drug interactions. Journal of the American College of Cardiology, 57(11): 1251-1263. https://doi.org/10.1016/j.jacc.2010.11.024   [Google Scholar] PMid:21392639
  4. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, and Scirica BM (2010). Clopidogrel with or without omeprazole in coronary artery disease. New England Journal of Medicine, 363(20): 1909-1917. https://doi.org/10.1056/NEJMoa1007964   [Google Scholar] PMid:20925534
  5. Brophy JM, Babapulle MN, Costa V, and Rinfret S (2006). A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. American Heart Journal, 152(2): 263-269. https://doi.org/10.1016/j.ahj.2005.08.023   [Google Scholar] PMid:16875906
  6. Collet JP, Silvain J, Bellemain-Appaix A, and Montalescot G (2014). Pretreatment with P2Y12 inhibitors in Non–ST-segment–elevation acute coronary syndrome: An outdated and harmful strategy. Circulation, 130(21): 1904-1914. https://doi.org/10.1161/CIRCULATIONAHA.114.011320   [Google Scholar] PMid:25403596
  7. Crea F and Liuzzo G (2013). Pathogenesis of acute coronary syndromes. Journal of the American College of Cardiology, 61(1): 1-11. https://doi.org/10.1016/j.jacc.2012.07.064   [Google Scholar] PMid:23158526
  8. Focks JJ, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, and Verheugt FW (2013). Concomitant use of clopidogrel and proton pump inhibitors: Impact on platelet function and clinical outcome-a systematic review. Heart, 99(8): 520-527. https://doi.org/10.1136/heartjnl-2012-302371   [Google Scholar] PMid:22851683
  9. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, and Boschat J (2008). Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (omeprazole clopidogrel aspirin) study. Journal of the American College of Cardiology, 51(3): 256-260. https://doi.org/10.1016/j.jacc.2007.06.064   [Google Scholar] PMid:18206732
  10. Good CW, Steinhubl SR, Brennan DM, Lincoff AM, Topol EJ, and Berger PB (2012). Is there a clinically significant interaction between calcium channel antagonists and clopidogrel? Results from the clopidogrel for the reduction of events during observation (CREDO) trial. Circulation: Cardiovascular Interventions, 5(1): 77-81. https://doi.org/10.1161/CIRCINTERVENTIONS.111.963405   [Google Scholar] PMid:22319066
  11. Gremmel T, Durstberger M, Eichelberger B, Koppensteiner R, and Panzer S (2015). Calcium‐channel blockers attenuate the antiplatelet effect of clopidogrel. Cardiovascular Therapeutics, 33(5): 264-269. https://doi.org/10.1111/1755-5922.12138   [Google Scholar] PMid:26014752
  12. Gupta E, Bansal D, Sotos J, and Olden K (2010). Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Digestive Diseases and Sciences, 55(7): 1964-1968. https://doi.org/10.1007/s10620-009-0960-8   [Google Scholar] PMid:19731021
  13. Harmsze AM, Robijns K, Van Werkum JW, Breet NJ, Hackeng CM, Jurrien M, and Deneer VH (2010). The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thrombosis and Haemostasis, 103(05): 920-925. https://doi.org/10.1160/TH09-08-0516   [Google Scholar] PMid:20352154
  14. Henderson RA (2014). Ischaemic heart disease: Management of non-ST-elevation acute coronary syndrome. Medicine, 42(9): 505-511. https://doi.org/10.1016/j.mpmed.2014.06.003   [Google Scholar]
  15. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, and Rumsfeld JS (2009). Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA, 301(9): 937-944. https://doi.org/10.1001/jama.2009.261   [Google Scholar] PMid:19258584
  16. Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthélémy O, and Montalescot G (2010). Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19* 2 loss-of-function allele or proton pump inhibitor coadministration: A systematic meta-analysis. Journal of the American College of Cardiology, 56(2): 134-143. https://doi.org/10.1016/j.jacc.2009.12.071   [Google Scholar] PMid:20620727
  17. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, and Mamdani MM (2009). A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Cmaj, 180(7): 713-718. https://doi.org/10.1503/cmaj.082001   [Google Scholar] PMid:19176635 PMCid:PMC2659819
  18. Keeley EC, Boura JA, and Grines CL (2003). Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. The Lancet, 361(9351): 13-20. https://doi.org/10.1016/S0140-6736(03)12113-7   [Google Scholar]
  19. Kreutz RP, Stanek EJ, Aubert R, Yao J, Breall JA, Desta Z, and Flockhart DA (2010). Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: The clopidogrel Medco outcomes study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 30(8): 787-796. https://doi.org/10.1592/phco.30.8.787   [Google Scholar] PMid:20653354
  20. Kumar A and Cannon CP (2009). Acute coronary syndromes: Diagnosis and management, part I. Mayo Clinic Proceedings, 84(10): 917-938. https://doi.org/10.4065/84.10.917   [Google Scholar] PMid:19797781 PMCid:PMC2755812
  21. Kwok CS and Loke YK (2012). Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel. Drug Safety, 35(2): 127-139. https://doi.org/10.2165/11594900-000000000-00000   [Google Scholar] PMid:22204719
  22. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, and Bates ER (2003). Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug–drug interaction. Circulation, 107(1): 32-37. https://doi.org/10.1161/01.CIR.0000047060.60595.CC   [Google Scholar] PMid:12515739
  23. Ludman PF (2018). Percutaneous coronary intervention. Medicine, 46(9): 547-554. https://doi.org/10.1016/j.mpmed.2018.06.007   [Google Scholar]
  24. Macaione F, Montaina C, Evola S, Novo G, and Novo S (2012). Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent implantation. International Scholarly Research Network, 2012: 692761. https://doi.org/10.5402/2012/692761   [Google Scholar] PMid:22792485 PMCid:PMC3391936
  25. Malmström RE, Östergren J, Jørgensen L, Hjemdahl P, and CASTOR investigators (2009). Influence of statin treatment on platelet inhibition by clopidogrel–a randomized comparison of rosuvastatin, atorvastatin and simvastatin co‐treatment. Journal of Internal Medicine, 266(5): 457-466. https://doi.org/10.1111/j.1365-2796.2009.02119.x   [Google Scholar] PMid:19549094
  26. Nagavi JB, Gurupadayya B, and Anantharaju PG (2016). Omeprazole and atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation in patients undergoing percutaneous coronary intervention in a tertiary health care system: A prospective drug–drug interaction study. IJC Metabolic and Endocrine, 13: 35-40. https://doi.org/10.1016/j.ijcme.2016.09.004   [Google Scholar]
  27. Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER, and O'Donoghue ML (2013). Concomitant administration of clopidogrel with statins or calcium-channel blockers: Insights from the TRITON–TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel–thrombolysis in myocardial infarction 38). Journal American College of Cardiology: Cardiovascular Interventions, 6(12): 1275-1281. https://doi.org/10.1016/j.jcin.2013.06.014   [Google Scholar] PMid:24239201
  28. Peng Y, Chen M, Chai H, Liu XJ, Li Q, Wei JF, and Huang DJ (2011). Impact of combination of calcium-channel blockers with clopidogrel on clinical outcomes in patients with coronary artery disease. International Journal of Cardiology, 149(2): 274-276. https://doi.org/10.1016/j.ijcard.2011.02.057   [Google Scholar] PMid:21419502
  29. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, and Van Dyck N (2009). Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. New England Journal of Medicine, 360(10): 961-972. https://doi.org/10.1056/NEJMoa0804626   [Google Scholar] PMid:19228612
  30. Siller-Matula JM, Lang I, Christ G, and Jilma B (2008). Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. Journal of the American College of Cardiology, 52(19): 1557-1563. https://doi.org/10.1016/j.jacc.2008.07.055   [Google Scholar] PMid:19007592
  31. Smith JN, Negrelli JM, Manek MB, Hawes EM, and Viera AJ (2015). Diagnosis and management of acute coronary syndrome: An evidence-based update. The Journal of the American Board of Family Medicine, 28(2): 283-293. https://doi.org/10.3122/jabfm.2015.02.140189   [Google Scholar] PMid:25748771
  32. Thom T, Haase N, and Rosamond W et al (2006). Heart disease and stroke statistics—2006 update: A report from the American heart association statistics committee and stroke statistics subcommittee. Circulation, 113: e85– e151. https://doi.org/10.1161/CIRCULATIONAHA.105.171600   [Google Scholar] PMid:16407573
  33. Urtane I, Aitullina A, and Pukite K (2013). Clopidogrel and the possibility of drug–drug interaction in primary health care. Journal of Young Pharmacists, 5(1): 18-21. https://doi.org/10.1016/j.jyp.2013.01.002   [Google Scholar] PMid:24023447 PMCid:PMC3758091
  34. Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S, Xiang MX, and Zhou Q (2015). Pharmacokinetic drug interactions with clopidogrel: Updated review and risk management in combination therapy. Therapeutics and Clinical Risk Management, 11: 449-467. https://doi.org/10.2147/TCRM.S80437   [Google Scholar] PMid:25848291 PMCid:PMC4373598
  35. Xiao FY, Luo JQ, Liu M, Chen BL, Cao S, Liu ZQ, and Zhang W (2017). Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients. Scientific Reports, 7(1): 1-6. https://doi.org/10.1038/s41598-017-07736-1   [Google Scholar] PMid:28775293 PMCid:PMC5543069